Related references
Note: Only part of the references are listed.Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
Nicholas Turner et al.
BREAST CANCER RESEARCH AND TREATMENT (2022)
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
A. Brufsky et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2021)
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Jamal Majidpoor et al.
CLINICAL IMMUNOLOGY (2021)
Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
Arielle L. Heeke et al.
CANCER AND METASTASIS REVIEWS (2021)
PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer
Yuxiang Chen et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
The current knowledge concerning solid cancer and therapy
Masoud Najafi et al.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)
A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y. Ho et al.
CANCER (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso-Sousa et al.
CLINICAL CANCER RESEARCH (2020)
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway
Arielle L. Heeke et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
H. Iwata et al.
ANNALS OF ONCOLOGY (2020)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak et al.
JAMA ONCOLOGY (2019)
1174OPembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
L A Diaz et al.
ANNALS OF ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Elaine R. Mardis
GENOME MEDICINE (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions
Albrecht Stenzinger et al.
GENES CHROMOSOMES & CANCER (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Radiotherapy and immunotherapy: a synergistic effect in cancer care
Guy-Anne Turgeon et al.
MEDICAL JOURNAL OF AUSTRALIA (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
E. Senkus-Konefka et al.
EUROPEAN JOURNAL OF CANCER (2018)
The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity?
Zuzana Hlavata et al.
TARGETED ONCOLOGY (2018)
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
Ahmed A. Mostafa et al.
CANCERS (2018)
Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies
Qiang Wang et al.
CANCER LETTERS (2018)
Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2-metastatic breast cancer administered abemaciclib plus pembrolizumab.
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Analysis of germline BRCA1/2 mutated (gBRCAmut) hormone receptor-positive (HR plus ) and triple negative breast cancer (TNBC) treated with talazoparib (TALA).
Wolfgang Eiermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies
Carsten Denkert et al.
LANCET (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer
Emma Nolan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression
Jianqin Lu et al.
NATURE COMMUNICATIONS (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
PD-1/PD-L1 Pathway in Breast Cancer
Florian Schuetz et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
Oncolytic Viruses in Cancer Treatment A Review
Sean E. Lawler et al.
JAMA ONCOLOGY (2017)
Evaluation of dosing strategy for pembrolizumab for oncology indications
Tomoko Freshwater et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Current immunotherapeutic Strategies to enhance Oncolytic virotherapy
Daniel E. Meyers et al.
FRONTIERS IN ONCOLOGY (2017)
Awareness and current knowledge of breast cancer
Muhammad Akram et al.
BIOLOGICAL RESEARCH (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses
Peter Schmid et al.
CANCER RESEARCH (2017)
KEYNOTE-012: Long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC)
R. Nanda et al.
CANCER RESEARCH (2017)
Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery
Shawn Stapleton et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors
Miguel A. Villalona-Calero et al.
CANCER (2016)
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi et al.
CLINICAL CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Radiotherapy supports tumor-specific immunity by acute inflammation
Laura Surace et al.
ONCOIMMUNOLOGY (2016)
Antitumour responses induced by a cell-based Reovirus vaccine in murine lung and melanoma models
Ciorsdan A. Campion et al.
BMC CANCER (2016)
In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
Shigeto Ueda et al.
BRITISH JOURNAL OF CANCER (2016)
Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma
Keith A. Lawson et al.
CLINICAL CANCER RESEARCH (2016)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik et al.
CANCER DISCOVERY (2016)
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma (vol 15, pg 857, 2016)
Marios Giannakis et al.
CELL REPORTS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Immunogenic cell death
Abhishek D. Garg et al.
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Cancer and the Immune System: Basic Concepts and Targets for Intervention
Drew Pardoll
SEMINARS IN ONCOLOGY (2015)
Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
Kevin R. Kelly et al.
ONCOTARGET (2015)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Joseph G. Crompton et al.
CANCER RESEARCH (2015)
Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers
Pawel Domagala et al.
PLOS ONE (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
M. J. Duffy et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
Kirsten M. Timms et al.
BREAST CANCER RESEARCH (2014)
Role of PI3K/Akt signaling in memory 038 T cell differentiation
Eui Ho Kim et al.
FRONTIERS IN IMMUNOLOGY (2013)
Cell Cycle-Based Therapies Move Forward
Marcos Malumbres
CANCER CELL (2012)
Reovirus as a Viable Therapeutic Option for the Treatment of Multiple Myeloma
Chandini M. Thirukkumaran et al.
CLINICAL CANCER RESEARCH (2012)
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
Leisha A. Emens
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Signal Integration by Akt Regulates CD8 T Cell Effector and Memory Differentiation
Eui Ho Kim et al.
JOURNAL OF IMMUNOLOGY (2012)
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage et al.
NATURE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism
Andrew N. Macintyre et al.
IMMUNITY (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and Metabolism
Jonathan D. Powell et al.
IMMUNITY (2010)
Immune Therapy for Cancer
Michael Dougan et al.
ANNUAL REVIEW OF IMMUNOLOGY (2009)
mTOR regulates memory CD8 T-cell differentiation
Koichi Araki et al.
NATURE (2009)
Reovirus: Viral therapy for cancer 'as nature intended'
C. Comins et al.
CLINICAL ONCOLOGY (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release
Paola Marcato et al.
MOLECULAR THERAPY (2007)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
The pathology of familial breast cancer:: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2
SR Lakhani et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Reovirus oncolysis of human breast cancer
KL Norman et al.
HUMAN GENE THERAPY (2002)
Share Paper
